Cannabinoids and Stroke: Promising Preclinical Findings
Stroke is a medical emergency caused either by a blocked blood vessel supplying the brain or by bleeding from a ruptured vessel. Ischemic strokes account for about 87% of strokes in the United States, while hemorrhagic strokes make up most of the remainder. Both types can cause permanent disability or death, and rapid diagnosis and treatment are essential. The American Stroke Association explains the main types of stroke and their treatments.
Research into cannabinoids has raised questions about whether compounds such as cannabidiol (CBD) or drugs that activate cannabinoid receptors could eventually help limit brain injury after an ischemic stroke. However, the evidence cited in support of this possibility comes primarily from laboratory and animal studies—not clinical trials showing that cannabis or CBD improves outcomes in people with stroke.
A 2013 review in the British Journal of Clinical Pharmacology, “Is the cardiovascular system a therapeutic target for cannabidiol?”, summarized findings from isolated blood vessels, animal models and other preclinical research. The review reported that CBD could relax isolated arteries and appeared to reduce vascular inflammation or injury in some experimental settings. It also discussed studies in animal models of cerebral ischemia and reperfusion—a period when blood flow returns after being interrupted.
Those findings are biologically interesting, but they do not establish that CBD treats stroke in humans. The review’s authors specifically noted that further research was needed to determine whether the observed effects would occur in people.
Another frequently cited study, published in Microvascular Research in 2009, examined CB2 receptor activation during cerebral ischemia and reperfusion. In a mouse model, treatment with a selective CB2 receptor agonist reduced several signs of microvascular dysfunction, including blood-brain barrier disruption, brain swelling and neurological impairment. The study also found larger infarcts and worse neurological outcomes in mice lacking the CB2 receptor.
Importantly, this experiment did not test smoked cannabis, medical marijuana or an over-the-counter CBD product. It used a specific experimental compound in animals. The treatment was administered before or up to three hours after the induced ischemic injury, but that result cannot be translated directly into a recommendation for people experiencing a stroke.
Human evidence on cannabis and stroke remains limited and mixed. A 2021 systematic review of available studies found that stroke was reported somewhat more often among cannabis users, but the authors emphasized the limitations of the evidence, including inconsistent definitions of cannabis exposure and the influence of other risk factors. The American Heart Association’s scientific statement on marijuana and brain health likewise describes unresolved questions and notes that some studies have associated cannabis use with stroke, while others have not found a clear relationship after accounting for factors such as tobacco use.
There is currently no established role for cannabis or CBD in emergency stroke care, stroke prevention or the reversal of permanent brain damage. The U.S. Food and Drug Administration states that it has not approved cannabis to treat any disease and has approved purified CBD only for certain seizure disorders—not for stroke. Unregulated cannabis and CBD products may also vary in strength and can interact with prescription medicines.
People with possible stroke symptoms should call 911 immediately rather than using cannabis or delaying hospital care. Depending on the type of stroke and the results of brain imaging, treatment may include clot-dissolving medication, mechanical clot removal, blood-pressure management, surgery or other specialized interventions. Cannabinoid-based therapies may remain a subject for future research, but promising laboratory results are not a substitute for proven stroke treatment.
